Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.
Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. Schneeweiss-Gleixner M, et al. Among authors: herndlhofer s. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21. EBioMedicine. 2019. PMID: 31761618 Free PMC article.
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Aichberger KJ, et al. Among authors: herndlhofer s. Eur J Clin Invest. 2007 Oct;37(10):808-13. doi: 10.1111/j.1365-2362.2007.01859.x. Epub 2007 Aug 28. Eur J Clin Invest. 2007. PMID: 17727673
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P. Wacheck V, et al. Among authors: herndlhofer s. Cancer Manag Res. 2011;3:157-75. doi: 10.2147/CMR.S19341. Epub 2011 May 10. Cancer Manag Res. 2011. PMID: 21625399 Free PMC article.
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P. Herrmann H, et al. Among authors: herndlhofer s. Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993666 Free PMC article.
32 results